首页 | 官方网站   微博 | 高级检索  
     

MA诱导方案与DA诱导方案对老年急性髓系白血病患者血清炎症因子及复发率的影响
引用本文:宋通微,杜 新,陈晓冰,李雄根,曹轶璇.MA诱导方案与DA诱导方案对老年急性髓系白血病患者血清炎症因子及复发率的影响[J].现代生物医学进展,2021(1):79-82.
作者姓名:宋通微  杜 新  陈晓冰  李雄根  曹轶璇
作者单位:广州医科大学研究生院 广东 广州 510182;深圳市人民医院全科医学科 广东 深圳 518020;广州医科大学研究生院 广东 广州 510182;深圳市第二人民医院血液内科 广东 深圳 518119;深圳市人民医院血液内科 广东 深圳 518020
基金项目:广东省科技计划项目(2016A020216071)
摘    要:目的:探讨米托蒽醌联合阿糖胞苷(MA方案)与柔红霉素联合阿糖胞苷(DA方案)对老年急性髓系白血病(AML)患者血清炎症因子及复发率的影响。方法:选取2015年1月~2018年1月期间深圳市人民医院收治的老年AML患者129例,根据治疗方案的不同将患者分为DA组(n=64,DA方案治疗)和MA组(n=65,MA方案治疗),比较两组患者疗效、炎症因子、不良反应及复发情况。结果:MA组治疗后的临床总有效率高于DA组(P<0.05)。两组患者治疗后血清干扰素γ诱导蛋白-10(IP-10)、巨噬细胞炎症蛋白-1α(MIP-1α)及可溶性细胞间黏附分子1(sICAM-1)水平均降低,且MA组低于DA组(P<0.05)。MA组完全缓解患者中累计复发率低于DA组(P<0.05)。两组不良反应发生率比较无差异(P>0.05)。结论:与DA诱导方案相比,MA诱导方案治疗老年AML患者,可有效改善炎症因子水平,减少复发,且用药安全性较好。

关 键 词:米托蒽醌  柔红霉素  老年  急性髓系白血病  炎症因子  复发率
收稿时间:2020/4/23 0:00:00
修稿时间:2020/5/18 0:00:00

The Effect of MA Induction and DA Induction on Inflammatory Factors and Recurrence Rate in Elderly Patients with Acute Myeloid Leukemia
SONG Tong-wei,DU Xin,CHEN Xiao-bing,LI Xiong-gen,CAO Yi-xuan.The Effect of MA Induction and DA Induction on Inflammatory Factors and Recurrence Rate in Elderly Patients with Acute Myeloid Leukemia[J].Progress in Modern Biomedicine,2021(1):79-82.
Authors:SONG Tong-wei  DU Xin  CHEN Xiao-bing  LI Xiong-gen  CAO Yi-xuan
Affiliation:(Graduate School of Guangzhou Medical University,Guangzhou,Guangdong,510182,China;Department of General medicine,Shenzhen People's Hospital,Shenzhen,Guangdong,518020,China;Department of Hematology,Shenzhen Second People's Hospital,Shenzhen,Guangdong,518119,China;Department of Hematology,Shenzhen People's Hospital,Shenzhen,Guangdong,518020,China)
Abstract:Objective: To investigate the effect of mitoxantrone combined with cytarabine(MA) and daunorubicin combined with cytarabine(DA) on inflammatory factors and recurrence rate in elderly patients with acute myeloid leukemia(AML). Methods: 129 elderly AML patients who were admitted to Shenzhen People’s Hospital from January 2015 to January 2018 were selected, the patients were divided into DA group(n=64, DA scheme treatment) and MA group(n=65, MA scheme treatment) according to different treatment schemes, the curative effect, inflammatory factors, adverse reactions and recurrence rate of the two groups were compared. Results: The total clinical effective rate of MA group was higher than that of DA group after treatment(P<0.05). The levels of IFN-γ-inducible protein-10(IP-10), macrophage inflammatory protein-1α(MIP-1α) and soluble intercellular adhesion molecule-1(sICAM-1) were all decreased of the two groups after treatment, and the level of MA group was lower than that of DA group(P<0.05). The cumulative recurrence rate in patients with complete remission of group MA was lower than that of group DA(P<0.05). There was no difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Compared with DA induction program, MA induction program can effectively improve the level of inflammatory factors and reduce the recurrence of elderly AML patients, and has better drug safety.
Keywords:Mitoxantrone  Daunorubicin  Elderly  Acute myeloid leukemia  Inflammatory factors  Recurrence rate
本文献已被 维普 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号